Julie Kim
CEO, President & DirectorMs. Julie Kim serves as CEO, President & Director of Takeda Pharmaceutical Company Limited since June 24, 2026. She joined the firm in January 2019. At Takeda Pharmaceutical Company Limited, she also served as Interim Head of Global Portfolio Division from November 2025 to June 24, 2026, as President of U.S. Business Unit & Interim Head of Global Portfolio from 2025, as President of the U.S. Business Unit & U.S. Country Head from April 1, 2022 to 2025, and as President of Plasma-Derived Therapies Business Unit from January 2019 to April 1, 2022. She serves as President, CEO & Representative Director of Takeda Ventures, Inc. since June 2026 and serves as CEO-Elect of Takeda Digital Ventures since April 2026. She serves as Board of Trustee of Boston Public Library Foundation, Inc. and serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). Her prior experience includes serving as CEO-Elect & Interim Head of Global Portfolio Division of Takeda Ventures, Inc. until June 2026, as Interim Head of Global Portfolio Division from 2025, and as President, U.S. Business Unit, U.S. Country Head, Interim Head of Global Portfolio Division. She also served as CEO-Elect & Interim Head of Global Portfolio Division of Takeda Digital Ventures until April 2026. Ms. Kim served as CEO-elect at Takeda in 2025. She served as Independent Non-Executive Director of Croda International Plc from September 1, 2021 to July 26, 2025. Prior to joining Takeda, she held roles of increasing responsibility at Baxter, Baxalta and Shire. Her global outlook is a result of having worked and lived in countries and regions, including the U.K., Switzerland, China's Hong Kong and the U.S. She has a Bachelor's in Economics from Dartmouth College and an M.B.A. from Kellogg School of Management.
Positions
- Company NameTakeda Pharmaceutical Company LimitedStock CodeTAKPositionCEO, President & Director
